Your browser doesn't support javascript.
loading
Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy.
Yuan, Zigao; Chen, Shaopeng; Gao, Chunmei; Dai, Qiuzi; Zhang, Cunlong; Sun, Qinsheng; Lin, Jin-Shun; Guo, Chun; Chen, Yuzong; Jiang, Yuyang.
Afiliação
  • Yuan Z; Department of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University,
  • Chen S; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Health Science Center, Shenzhen University, Shenzhen 518060, PR China.
  • Gao C; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; College of Chemistry and Chemical Engineering, Shenzhen University, Shenzhen 518060, PR
  • Dai Q; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.
  • Zhang C; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.
  • Sun Q; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.
  • Lin JS; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.
  • Guo C; Department of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China.
  • Chen Y; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Department of Pharmacy, Faculty of Science, National University of Singapore, 117543, S
  • Jiang Y; Department of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, Shenzhen Kivita Innovative Drug Discovery Institute, The Graduate School at Shenzhen, Tsinghua University,
Bioorg Chem ; 87: 200-208, 2019 06.
Article em En | MEDLINE | ID: mdl-30901675
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / DNA (Citosina-5-)-Metiltransferases / Histona Desacetilase 1 / Inibidores de Histona Desacetilases / DNA (Citosina-5-)-Metiltransferase 1 / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / DNA (Citosina-5-)-Metiltransferases / Histona Desacetilase 1 / Inibidores de Histona Desacetilases / DNA (Citosina-5-)-Metiltransferase 1 / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article